`
`Application No. 15/121,623
`
`- 4 -
`
`GEUIJEN er a].
`
`7.
`
`(Canceled)
`
`8.
`
`(Currently Amended) A—b+speerfieantrbedyeempfis+nga—firseb+nd+ng—arm—that—bmds
`
`:=--.-
`
`.
`
`:.
`
`- .-..-.-_. --
`
`-.
`
`::--.-
`
`.
`
`:5 Thebispecific
`
`antibody of claim 1, wherein the affinity (KD) of the second binding arm for an ErbB-3
`
`positive cell is equal to, or higher than, the affinity of the first binding arm for an ErbB-2
`
`positive cell.
`
`9.
`
`(Canceled)
`
`10. (Canceled)
`
`11. (Previously Presented) The bispecific antibody of claim 1, wherein the affinity (KD) of the
`
`second binding arm for an ErbB-3 positive cell is lower than or equal to 2.0 nM.
`
`12. (Previously Presented) The bispecific antibody of claim 1, wherein the affinity (KD) of the
`
`first binding arm for an ErbB-2 positive cell is lower than or equal to 5.0 nM.
`
`13. (Currently Amended) The bispecific antibody of claim 1, wherein the affinity (KD) of the
`
`bispecific antibody for a human breast cancer ET 474 cell[[s]] is lower than or equal to 5.0
`
`nM, and/or wherein the affinity of the bispecific antibody for a human breast cancer SK-BR
`
`3 cell[[s]] is lower than or equal to 5.0 nM.
`
`14-17. (Canceled)
`
`
`18. (Currently Amended) The bispecific antibody of claim [[1]] 2, wherein the cell is a human
`
`breast cancer BT-474 cell or a human breast cancer SK-BR 3 cell.
`
`19. (Previously Presented) The bispecific antibody of claim 1, comprising a binding arm that
`
`binds at least one amino acid of domain I of ErbB-2 selected from the group consisting of:
`
`T144, T164, R166, P172, G179, S180, R181, and surface-exposed amino acid residues that
`
`Atty. Dkt. No. 4096.0100002/DAS/PAC/PMR
`
`